CRVS Corvus Pharmaceuticals Inc

Price (delayed)

$1.1

Market cap

$51.21M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.79

Enterprise value

$25.87M

Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company. Corvus' lead product candidate is CPI-006, a humanized monoclonal antibody directed against CD73 that has exhibited immunomodulatory activity and activation of immune cells ...

Highlights
The EPS has increased by 11% QoQ
Corvus Pharmaceuticals's net income has increased by 8% QoQ
The debt has soared by 76% YoY but it has contracted by 8% from the previous quarter
The quick ratio has contracted by 18% from the previous quarter but it has grown by 4.5% YoY
Corvus Pharmaceuticals's equity has decreased by 17% YoY and by 10% QoQ

Key stats

What are the main financial stats of CRVS
Market
Shares outstanding
46.55M
Market cap
$51.21M
Enterprise value
$25.87M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.64
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$36.57M
EBITDA
-$36.19M
Free cash flow
-$27.84M
Per share
EPS
-$0.79
Free cash flow per share
-$0.6
Book value per share
$1.73
Revenue per share
$0
TBVPS
$1.99
Balance sheet
Total assets
$92.54M
Total liabilities
$12.16M
Debt
$3.13M
Equity
$80.39M
Working capital
$48.73M
Liquidity
Debt to equity
0.04
Current ratio
5.8
Quick ratio
5.62
Net debt/EBITDA
0.7
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-34.6%
Return on equity
-39.3%
Return on invested capital
-72.9%
Return on capital employed
-44.4%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

CRVS stock price

How has the Corvus Pharmaceuticals stock price performed over time
Intraday
1.85%
1 week
27.68%
1 month
11%
1 year
-43.01%
YTD
-54.36%
QTD
11.1%

Financial performance

How have Corvus Pharmaceuticals's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$30.28M
Net income
-$36.57M
Gross margin
N/A
Net margin
N/A
The operating income rose by 29% year-on-year and by 12% since the previous quarter
Corvus Pharmaceuticals's net income has increased by 8% QoQ

Growth

What is Corvus Pharmaceuticals's growth rate over time

Valuation

What is Corvus Pharmaceuticals stock price valuation
P/E
N/A
P/B
0.64
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has increased by 11% QoQ
The price to book (P/B) is 60% lower than the 5-year quarterly average of 1.6 and 42% lower than the last 4 quarters average of 1.1
Corvus Pharmaceuticals's equity has decreased by 17% YoY and by 10% QoQ

Efficiency

How efficient is Corvus Pharmaceuticals business performance
Corvus Pharmaceuticals's return on invested capital has increased by 16% QoQ
The company's return on assets rose by 4.9% QoQ
The ROE is up by 4.4% since the previous quarter

Dividends

What is CRVS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CRVS.

Financial health

How did Corvus Pharmaceuticals financials performed over time
The quick ratio has contracted by 18% from the previous quarter but it has grown by 4.5% YoY
CRVS's current ratio is down by 17% from the previous quarter but it is up by 3.8% YoY
The debt is 96% less than the equity
The debt to equity has soared by 100% year-on-year
The debt has soared by 76% YoY but it has contracted by 8% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.